Completed PHASE1/PHASE2 INTERVENTIONAL 2-arm NCT04784481

Ivermectin Reproposing for Mild Stage COVID-19 Outpatients (IVER-Leve)

Ivermectin Reproposing for COVID-19 Treatment in Outpatients With Mild Stage

Sponsor: Ministry of Public Health, Argentina

Conditions Covid19 SARS (Severe Acute Respiratory Syndrome)

Interventions Ivermectin

Updated 5 times since 2021 Last updated: Apr 22, 2021 Started: Sep 20, 2020 Primary completion: Dec 20, 2020 Completion: Jan 18, 2021

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE1/PHASE2 trial investigates Covid19 and SARS (Severe Acute Respiratory Syndrome) and is currently completed. Ministry of Public Health, Argentina leads this study, which shows 5 recorded versions since 2020 — indicating limited longitudinal coverage. Longitudinal tracking of infectious disease trials helps identify durability of treatment effects.

Status Flow

Change History

5 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE1/PHASE2
Sep 2024 — Sep 2025 [monthly]

Completed PHASE1/PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1/PHASE2

Phase: PHASE1_PHASE2 → PHASE1/PHASE2
May 2021 — Jul 2024 [monthly]

Completed PHASE1_PHASE2
Apr 2021 — May 2021 [monthly]

Completed PHASE1_PHASE2

First recorded

Sep 2020

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Ministry of Public Health, Argentina

Data source: Ministry of Public Health, Argentina

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• San Miguel de Tucumán, Argentina